Which statement supports timely stroke treatment with tPA?

• A. Timely administration of tPA within the approved window improves outcomes
• B. Delays improve patient safety
• C. Corticosteroids are first-line care
• D. tPA is never used in stroke

Answer: (A)

Prompt reperfusion of the brain is crucial in acute ischemic stroke. Administering tPA within the approved time window dissolves the clot quickly, restoring blood flow to endangered tissue and limiting the size of the infarct. This translates into better functional recovery and fewer disabilities because neurons survive when perfusion is restored early. The benefit of tPA diminishes as time passes—the longer the tissue goes without blood flow, the more brain cells die and the risk of hemorrhagic transformation increases. So, delays do not enhance safety; they worsen outcomes.

Corticosteroids are not a standard first-line treatment for acute ischemic stroke and have not been shown to improve recovery when used with thrombolysis; they can add unnecessary risks. And tPA is not never used in stroke; it is an approved, evidence-based therapy for eligible patients with acute ischemic stroke when given within the time window after careful assessment to exclude hemorrhage and other contraindications.